NME1-NME2: A Potential Drug Target for Neurological Disorders
NME1-NME2: A Potential Drug Target for Neurological Disorders
NME1-NME2 (Nm23-H2), a protein that is expressed in various tissues throughout the body, has been identified as a potential drug target or biomarker. NME1-NME2 is a subunit of the neural stem cell surface antigen (NSCAM) family, which is known to play a crucial role in the development and maintenance of neural stem cells.
NME1-NME2 has been shown to be involved in various cellular processes that are important for neural stem cell survival and proliferation. For example, studies have shown that NME1-NME2 is involved in the regulation of cell adhesion, which is critical for the maintenance of stem cell stem-like properties. Additionally, NME1-NME2 has been shown to be involved in the regulation of cell survival, as well as the regulation of cellular processes such as cell cycle progression and apoptosis.
Due to its involvement in these processes, NME1-NME2 has been identified as a potential drug target or biomarker for a variety of neurological and psychiatric disorders. For example, NME1-NME2 has been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Additionally, NME1-NME2 has been shown to be involved in the development and progression of psychiatric disorders, including depression and anxiety.
One potential approach to targeting NME1-NME2 as a drug target is to use small molecules or antibodies that can modulate its activity. For example, researchers have shown that inhibiting NME1-NME2 activity can protect neural stem cells from oxidative stress, which can lead to cell death. Additionally, researchers have shown that antibodies that recognize and target NME1-NME2 can protect against neurotoxicity, which is a common complication in animal models of neurodegenerative diseases.
Another approach to targeting NME1-NME2 is to use drugs that specifically modulate its expression. For example, researchers have shown that inhibiting the activity of NME1-NME2 can lead to a decrease in the level of NME1-NME2 in brain tissue, which can potentially lead to the activation of other genes that are involved in neurodegeneration. Additionally, researchers have shown that drugs that specifically modulate NME1-NME2 expression can be effective in animal models of neurodegenerative diseases.
Overall, NME1-NME2 is a protein that is involved in various cellular processes that are important for neural stem cell survival and proliferation. As a result, it has been identified as a potential drug target or biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of NME1-NME2 in neural stem cell biology and to develop effective treatments for disorders that are related to its activity.
Protein Name: NME1-NME2 Readthrough
The "NME1-NME2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NME1-NME2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3 | NOS3 | NOSIP | NOSTRIN | Notch ligands | Notch receptor | Notch Transcriptional Activation Complex | NOTCH1 | NOTCH2 | NOTCH2NLA | NOTCH2NLC | NOTCH3 | NOTCH4 | NOTO | NOTUM | NOVA1 | NOVA1-DT | NOVA2 | NOX1 | NOX3 | NOX4 | NOX5 | NOXA1
